Option chain shows key data for Touchstone Bankshares Inc Com's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Touchstone Bankshares Inc Com.

Touchstone Bankshares Inc Com (OTC:TSBA) Stock, Option Chain

Touchstone Bankshares

News

Intraday Update

Markets

Movers

Trading Ideas

AAXN

ADUS

AIQUF

ALLE

ALNY

AMED

AMTB

AMWD

ANCUF

APPF

ARWR

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BANX

BF-A

BF-B

BLDR

BLMN

BMCH

BNCDY

BNTGF

BRLXF

BTBIF

BURL

CACI

CARE

CATO

CBFV

CBNK

CBRE

CCXI

CDAY

CLLXF

CMTL

CNNE

CNSWF

COFS

COLL

CRHCF

CSLLY

CTAC

CVNA

DOOO

DOOR

DSDVF

DSDVY

DSGX

DXCM

EBSB

EPAM

EPIX

ESNT

EVER

EVRI

FBHS

FISI

FIVN

FLXN

FSBW

FSUGY

GAIN

GEAGY

GMED

GNGBY

GNRC

GWRE

GWRS

GZTGF

HCCI

HNGR

Stocks That Hit 52-Week Highs On Tuesday

Touchstone Bankshares Inc Com

Northland Capital Markets analyst Mike Grondahl maintains Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) with a Outperform and raises the price target from $10 to $10.5.

Price Target

Analyst Ratings

LGCY

Northland Capital Markets Maintains Outperform on Legacy Education, Raises Price Target to $10.5

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

Reiteration

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Westlake Securities analyst Casey Ryan maintains Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and raises the price target from $2.65 to $4.67.

VRAR

Westlake Securities Maintains Buy on Glimpse Group, Raises Price Target to $4.67

TSLA: -6% &#x7C; <a href="https://www.benzinga.com//node/42613402">NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025</a>
&nbsp;
NKE: -6% &#x7C; <a href="https://www.benzinga.com//node/42605414">Nike Q2 Earnings: Revenue Beat, EPS Beat, Shares Jump, and then reverse — 'Nike Being Nike Again'</a>
&nbsp;
HUMA: 91% &#x7C; <a href="https://www.benzinga.com//node/42609617">FDA Approves Humacyte's SYMVESS For Treating Extremity Vascular Injuries</a>

HUMA

TSLA

Market-Moving News for December 20th

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42607141/tryngolza-olezarsen-approved-in-u-s-as-first-ever-treatment-for-adults-living-with-familial-chylom" rel="noreferrer noopener">lead to acute pancreatitis (AP)</a>.
SHTG is&nbsp;a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level.&nbsp;
Tryngolza is the first-ever&nbsp;FDA-approved treatment that significantly and substantially reduces&nbsp;triglyceride levels in adults with FCS and provides a clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).
Tryngolza is self-administered via an auto-injector once-monthly.
The FDA approval was based on Phase 3 Balance trial data in adult patients.
In the Balance study, Tryngolza 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084).&nbsp;
Reductions from baseline to 12 months were further improved, with Tryngolza achieving a placebo-adjusted 57% mean triglyceride reduction.&nbsp;
Tryngolza also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the Tryngolza group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group.&nbsp;
Tryngolza will be available in the U.S. before year end.
Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2, and ESSENCE – for SHTG. Olezarsen has not been reviewed or approved for SHTG.
In November, Ionis Pharmaceuticals announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome (AS). The trial is expected to start in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769886/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome" rel="noreferrer noopener">the first half of 2025</a>.
AS typically presents in infancy and is characterized by profound intellectual disability, impaired verbal abilities, and severe motor impairment.
Price Action: At last check on Friday, IONS stock was up 3.79% at $36.94 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600482/mercks-investigational-two-drug-regime-for-hiv-meets-primary-goal-in-two-late-stage-trials" target="_blank" rel="noreferrer noopener">Merck&#8217;s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials</a></li>
</ul>

Biotech

Health Care

General

IONS

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

JP Morgan analyst Michael Mueller upgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Neutral to Overweight and raises the price target from $122 to $125.

Upgrades

JP Morgan Upgrades Federal Realty Investment to Overweight, Raises Price Target to $125

Further information regarding the final result of the offer, including the number of shares tendered, will be disclosed in JBT's upcoming 8-K filing.

JBT Says Voluntary Takeover Offer For Marel hf. Expired; Has Now Satisfied All Conditions To Offer, Including Minimum Acceptance Condition

JP Morgan analyst Anthony Paolone upgrades Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) from Neutral to Overweight and raises the price target from $45 to $49.

JP Morgan Upgrades Kilroy Realty to Overweight, Raises Price Target to $49

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with a Buy and maintains $45 price target.

ORKA

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target

Mizuho analyst David Bellinger maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Neutral and raises the price target from $72 to $80.

Mizuho Maintains Neutral on CarMax, Raises Price Target to $80

JP Morgan analyst Anthony Paolone downgrades Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) from Overweight to Neutral and announces $26 price target.

Downgrades

JP Morgan Downgrades Kimco Realty to Neutral, Announces $26 Price Target

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $60 price target.

Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

TAOP

Taoping Announced That It Received Notification From The Nasdaq Stock Market Confirming The Company Has Been Granted An Additional 180 Calendar Day Period For Compliance Under Its Minimum Bid Price Requirement Through June 16, 2025

JP Morgan analyst Michael Mueller downgrades Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Overweight to Neutral and announces $19 price target.

JP Morgan Downgrades Healthcare Realty Trust to Neutral, Announces $19 Price Target

JP Morgan analyst Michael Mueller downgrades Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Overweight to Neutral and lowers the price target from $78 to $75.

LINE

JP Morgan Downgrades Lineage to Neutral, Lowers Price Target to $75

HC Wainwright &amp; Co. analyst Arthur He maintains LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) with a Buy and lowers the price target from $6 to $2.

LVTX

HC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $2

Contracts

AECOM Says Awarded Several New Positions On Additional AMP8 UK Water Infrastructure Frameworks

SBC Medical Group Holdings Says Its Unit SBC Medical Group Co. Has Decided To Sell All Shares Of Its Subsidiaries, SBC Kijimadaira Resort Co And Skynet Academy Co

XCharge said it is committed to sound corporate governance and transparent communication with its shareholders. The Company's operations continue as normal, and its financial condition remains strong.
 &nbsp;

XCHG Says It Is Not Aware Of Any Material News Or Events That Would Account For Unusual Trading Activity

<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">December 17, 2024 NHTSA CAMPAIGN NUMBER: 24V935000</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">TPMS Light May Not Remain Illuminated/FMVSS 138</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Software Update Repairs Recall</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Driving with improperly inflated tires increases the risk of a crash.</a>
NHTSA Campaign Number:&nbsp;24V935000
Manufacturer&nbsp;Tesla, Inc.
Components&nbsp;TIRES
Potential Number of Units Affected&nbsp;694,304
Summary
Tesla, Inc. (Tesla) is recalling certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles. The tire pressure monitoring system (TPMS) warning light may not remain illuminated between drive cycles, failing to warn the driver of low tire pressure. As such, these vehicles fail to comply with the requirements of Federal Motor Vehicle Safety Standard number 138, "Tire Pressure Monitoring Systems."
Remedy
Tesla released an over-the-air (OTA) software update, free of charge. Owner notification letters are expected to be mailed February 15, 2025. Owners may contact Tesla customer service at 1-877-798-3752. Tesla's number for this recall is SB-24-00-018.
Notes
Owners may also contact the National Highway Traffic Safety Administration Vehicle Safety Hotline at 1-888-327-4236 (TTY 1-800-424-9153), or go to <a href="http://www.nhtsa.gov" title="www.nhtsa.gov">www.nhtsa.gov</a>.

NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025

Touchstone Bankshares appoints CFO

Touchstone Bank GAAP EPS of $0.32, revenue of $6.10M

First National to buy Touchstone Bankshares in all-stock deal

Touchstone Bank GAAP EPS of $0.10, revenue of $5.91M

Touchstone Bank GAAP EPS of $0.14, revenue of $6.02M

Touchstone Bank goes ex dividend tomorrow

FXNC

TSBA

Small Cap

Press Releases

Touchstone Bank Names Adam Sothen Executive Vice President and Chief Financial Officer

Earnings

Touchstone Bankshares Reports Financial Results for the Fourth Quarter and Full Year 2023

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Touchstone Bankshares, Inc. - TSBA

Touchstone Bankshares, Inc. Reports Financial Results for the First Quarter 2024

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Touchstone Bankshares, Inc. - TSBA

FIRST NATIONAL CORPORATION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of First National Corporation - FXNC

Touchstone Bankshares, Inc. Reports Financial Results for the Second Quarter 2024

Dividends

Touchstone Bankshares, Inc. Declares Pro Rata Annual Cash Dividend in Anticipation of the Proposed Merger with First National Corporation

Comments

Touchstone Bankshares Inc Com

Touchstone Bankshares Inc Com (TSBA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga